Determination Of Neoantigens For Personalized Vaccination Of Glioblastomas

Amartya Nandi

B.Sc Industrial Microbiology Department of Biotechnology GGDSD, Panjab University

*Corresponding author: Nandi A, Department of Biotechnology GGDSD, Panjab University ; Tel : 84651215921 E-mail: amartyanandi.research20@gmail.com

Citation: Nandi A,(2021) Determination of Neoantigens for Personalized Vaccination of Glioblastomas. Cell Bio

Glioblastomas are the most aggressive and most founded type of common type of CNS cancer which are mainly classified into 2 major groups i.e. low grade gliomas (LGG) and high grade gliomas (HGG) and exhibits both intra and inter tumor heterogeny LGG are showing low proliferation rate and further divided two sub types that are Grade I and Grade II which are commonly infiltrative and recur and they occur usually due to mutations in IDH-1 and IDH-2 genes. Whereas, HGG are further divided two sub types Grade III and Grade IV showing nuclear atypia and most aggressive necrosis and high angiogenesis rate. Large scale genomic and proteomic analysis of GBM tumor cells has uncovered potential drug targets. So, it’s became important to find the novel biomarkers and precision medicine for GBM. As, current treatment opportunity are maximal surgical resection, followed by temozolomide and radiation. Due to the invasive nature of GBM, surgical resection rarely eliminates all tumor cells, and postsurgical treatment is usually necessary to prevent recurrence.